Method for treatment of blood tumor using anti-TIM-3 antibody
View Patent ↗Disclosed is a therapeutic method including administering a TIM-3 antibody or its TIM-3 binding fragment to a subject who is suspected to be suffering from blood tumor and in whom TIM-3 has been expressed in a Lin(−)CD34(+)CD38(−) cell fraction of bone marrow or peripheral blood or a subject who has been received any treatment for blood tumor. Conceived diseases include those diseases which can be treated through the binding or targeting of the TIM-3 antibody or its TIM-3 binding fragment to blood tumor cells (AML cells, CML cells, MDS cells, ALL cells, CLL cells, multiple myeloma cells, etc.), helper T cell (e.g., Th1 cells, Th17 cells), and antigen-presenting cells (e.g., dendritic cells, monocytes, macrophages, and cells resembling to the aforementioned cells (hepatic stellate cells, osteoclasts, microglial cells, intraepidermal macrophages, dust cells (alveolar macrophages), etc)).
1. A method for treating a tumor in a subject, comprising administering an anti-T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) antibody or its TIM-3 binding fragment to the subject who is suspected to have a tumor in which a cell expressing TIM-3 is recognized in bone marrow or peripheral blood, wherein the cell is at least one cell fraction of
(a) Lin(−)CD34(+)CD38(+) or
(b) Lin(−)CD34(−).
2. The method according to claim 1 , wherein the tumor is lymphoma, myelodysplastic syndromes, acute myeloid leukemia or chronic myeloid leukemia.
3. The method according to claim 1 , wherein the blood tumor is recurrence and/or refractory.
4. The method according to claim 1 , wherein the anti-TIM-3 antibody is an antibody which has a constant region originated from a human species.
5. The method according to claim 1 , wherein the anti-TIM-3 antibody is at least one antibody selected from the group consisting of a monoclonal antibody, a chimeric antibody, a humanized antibody and a human antibody.
6. The method according to claim 1 , wherein the anti-TIM-3 monoclonal antibody is an antibody having ADCC activity and/or CDC activity.
7. A method for decreasing a tumor in a subject comprising administering an anti-T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) antibody or its TIM-3 binding fragment to the subject who is suspected to have tumor in which a cell expressing TIM-3 is recognized in bone marrow or peripheral blood, wherein the tumor is recurrence and/or refractory.
8. The method according to claim 7 , wherein the cell is at least one cell fraction selected from the group consisting of (a) to (c):
(a) Lin(−)CD34(+)CD38(−),
(b) Lin(−)CD34(+)CD38(+), and
(c) Lin(−)CD34(−).
9. The method according to claim 8 , wherein the cell fraction (a) is a leukemia stem cell.
10. The method according to claim 8 , wherein the cell fraction (b) or (c) is a blast cell.
11. The method according to claim 7 , wherein the tumor is lymphoma, myelodysplastic syndromes, acute myeloid leukemia or chronic myeloid leukemia.
12. The method according to claim 7 , wherein the anti-TIM-3 antibody is an antibody which has a constant region originated from a human species.
13. The method according to claim 7 , wherein the anti-TIM-3 antibody is at least one antibody selected from the group consisting of a monoclonal antibody, a chimeric antibody, a humanized antibody and a human antibody.
14. The method according to claim 7 , wherein the anti-TIM-3 monoclonal antibody is an antibody having ADCC activity and/or CDC activity.
15. The method according to claim 1 , wherein the cell fraction further comprises (c) Lin(−)CD34(+)CD38(−).
16. The method according to claim 1 , wherein the cell fraction (a) or (b) is a blast cell.
17. The method according to claim 15 , wherein the cell fraction (c) is a leukemia stem cell.
18. The method according to claim 15 , wherein the cell fraction is a cell fraction selected from the group consisting of (a) and (b), (a) and (c), (b) and (c), and (a), (b) and (c).